Lancet Oncology SJR and Scopus Metrics: What the Numbers Actually Tell Authors
Lancet Oncology's Scopus profile confirms what oncology authors already suspect. The useful question is whether your paper is truly global and practice-changing enough for the journal.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Quick answer: Lancet Oncology sits in the tiny uppermost tier of oncology journals under Scopus-style metrics. Current Scopus-linked ranking systems report a 2024 SJR of 12.868, a CiteScore of 63.2, and top-1-percent standing. That confirms major global prestige, but the submission decision still depends on whether the manuscript is broad and practice-changing enough for a Lancet-family oncology audience.
The core metric picture
Metric | 2024 value | What it tells you |
|---|---|---|
SJR | 12.868 | Prestige-weighted influence is exceptional |
CiteScore | 63.2 | Four-year citation performance is elite |
Quartile | Q1 | The journal remains firmly top-tier |
Percentile | 99th percentile | The journal sits in the top 1 percent of tracked journals |
Category standing | Oncology leader | The journal belongs in the very top cancer-journal tier |
JCR context | Impact factor 35.9 | Web of Science tells the same flagship clinical story |
The useful reading is that Lancet Oncology is not just a strong cancer journal. It is one of the few journals where clinical oncology papers can quickly become international reference points.
What the metrics actually help with
They help explain what kind of journal this is:
- stronger for globally relevant clinical oncology than for narrow disease-specific reporting
- built for papers that influence treatment thinking quickly
- different from biology-first oncology flagships and different from more method-focused clinical titles
That is useful when the shortlist includes Lancet Oncology, JCO, JAMA Oncology, or a strong specialty journal.
What the metrics do not answer
They do not tell you:
- whether the paper is broad enough internationally
- whether the study truly changes practice
- whether another elite oncology journal is a better stylistic fit
- whether the evidence package is actually decisive enough
Those are still the real editorial questions.
Why the profile matters for authors
At this SJR level, Lancet Oncology can be severe about consequence. The journal's profile reflects a specific editorial product:
- high-impact clinical oncology evidence
- broad relevance beyond one institutional or disease niche
- papers that oncologists, policy readers, and guideline thinkers keep using
- work that feels urgent enough to matter quickly
That is why the numbers are useful. They show the journal has enough authority that it does not need to stretch for merely respectable oncology studies.
What should drive the submission decision instead
The better question is whether the manuscript is truly a Lancet Oncology paper.
That is why the better next reads are:
- Lancet Oncology submission guide
- Lancet Oncology impact factor
- JCO SJR and Scopus metrics
- JAMA Oncology submission guide
If the paper is strong but still too narrow, too local, or not practice-changing enough, the metrics do not rescue the mismatch. They only explain why the journal can reject many good cancer papers.
Practical verdict
Lancet Oncology has a genuine flagship Scopus profile for clinical oncology. That makes it a powerful target when the manuscript is globally relevant, clinically consequential, and urgent enough to matter across a broad oncology readership.
But the useful takeaway is still fit, not seduction. If the paper is not really that broad or that decisive, the metric is already warning you. A free Manusights scan is the fastest way to pressure-test that before submission.
Sources
- 1. Lancet Oncology metrics page, JRank.
- 2. Lancet Oncology information for authors, The Lancet.
- 3. Lancet Oncology submission guide, Manusights.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.